Compare ATHM & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATHM | HROW |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2013 | N/A |
| Metric | ATHM | HROW |
|---|---|---|
| Price | $17.95 | $35.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $28.00 | ★ $69.86 |
| AVG Volume (30 Days) | 547.7K | ★ 558.3K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $31.79 |
| Revenue Next Year | $4.82 | $49.04 |
| P/E Ratio | $12.13 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.74 | $21.18 |
| 52 Week High | $29.92 | $54.98 |
| Indicator | ATHM | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 44.29 |
| Support Level | $17.87 | $32.79 |
| Resistance Level | $19.87 | $37.41 |
| Average True Range (ATR) | 0.49 | 1.61 |
| MACD | 0.18 | 0.67 |
| Stochastic Oscillator | 72.73 | 57.31 |
Founded in 2008 as a media content platform, Autohome is the leading online automobile platform in China, ranking first among automotive service platforms in terms of mobile daily active users, according to QuestMobile. Through its two websites, autohome.com.cn and che168.com, Autohome delivers comprehensive, independent and interactive content and tools to automobile consumers as well as a full suite of services to automakers and dealers. According to iResearch, the company was the largest online automotive advertising and lead generation service provider, in terms of media services and lead generation revenue, in China's online auto platform media advertising market.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.